Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.
about
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunctionDevelopment of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioidsPersistent constipation and abdominal adverse events with newer treatments for constipation.Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitorsMethylnaltrexone: the evidence for its use in the management of opioid-induced constipation.Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipationRecent advances in the use of opioids for cancer painUtilization of methylnaltrexone (relistor) for opioid-induced constipation in an oncology hospital.Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteersStandardized application of laxatives and physical measures in neurosurgical intensive care patients improves defecation pattern but is not associated with lower intracranial pressure.Constipation: opioid antagonists in people prescribed opioidsFixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension.6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer painEfficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomesPhysiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide.The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilitiesOpioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.Opioid-induced bowel dysfunction.Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadoneOral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain
P2860
Q27010907-E212E1C6-A32E-436D-A8D7-A8904CE73B01Q30989361-FD0F792F-0730-4F15-99DE-6FA16089A6CDQ33468562-9AAB3DF4-2FA7-4E56-A754-E6886B7CA50EQ33702325-6D3369E7-8176-4778-B77B-EF2040CBAF06Q33973870-CF73CB41-913D-4DD6-A4AE-A68C984F3BC4Q34146166-0FA1F702-1355-4D5D-978A-C601EC10FDE9Q34418203-D6251888-528A-4EEB-A1BE-7E174D9A8141Q34614438-4D1459F7-7D40-43AB-9AF5-F229721CF4C1Q34966995-451932B3-9B6B-487A-A19E-AC40C7B70067Q34979930-E5F4EA35-1CFB-41D8-8BBB-F8C1F66986A5Q35770714-37C840BE-C82D-4A74-A2B2-8E98F7CE8AAAQ35822213-6A070BEC-0801-4878-98E8-7EDC3873E43FQ36090988-61AED3AD-5F71-4534-8D3C-678D521B29ACQ36253231-A2ACE741-2426-47FC-BAF8-E31C90684B00Q36384732-331562F1-9C5E-4A6B-8385-1746FE3D0600Q36480105-98E58414-D519-4FCC-8C67-A32EC4E87635Q36696556-86691CF9-4770-493A-9F4A-553A66D56E19Q37491434-8F5F3255-215F-4435-A455-DD9FE7BE2B36Q37916266-DF75FF86-EBAB-4199-B41E-63A763FAD30BQ38116004-FB5EFE1E-D721-45D9-A656-37647BBA006CQ39051851-02F7CF42-9785-454B-97A7-DC947FFC1E76Q39151326-D319B123-4705-45B4-A1AE-A864AD0AF9AEQ42323281-FF93309F-7576-4513-A09D-314A7B5C0550Q58694488-8DA68658-868A-4828-ADD5-D358EDCA054AQ58786001-75B269E1-0352-48E2-9727-4CAD4F675F8A
P2860
Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Methylnaltrexone for treatment ...... in advanced illness patients.
@ast
Methylnaltrexone for treatment ...... in advanced illness patients.
@en
type
label
Methylnaltrexone for treatment ...... in advanced illness patients.
@ast
Methylnaltrexone for treatment ...... in advanced illness patients.
@en
prefLabel
Methylnaltrexone for treatment ...... in advanced illness patients.
@ast
Methylnaltrexone for treatment ...... in advanced illness patients.
@en
P2093
P1476
Methylnaltrexone for treatment ...... in advanced illness patients.
@en
P2093
Arthur G Lipman
Charles Wellman
Donna S Zhukovsky
George Wilson
Jay Thomas
Michelle L Boatwright
Nancy Stambler
Neal Slatkin
Richard Stephenson
Robert Israel
P577
2009-01-01T00:00:00Z